ERBB2 and breast carcinoma: Therefore, the prognosis associated with HER2-positive breast cancer is usually poor and most patients with HER2-positive breast cancer are resistant to targeted hormonal therapy.The most common drugs for treating HER2-positive breast cancer include trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine.